Easton Pharmaceuticals Announces Update to Its Cancer Drug Initiative: Majority Acquisition, Patent Strategy & Clinical Devel...
March 25 2014 - 8:44AM
Marketwired
Easton Pharmaceuticals Announces Update to Its Cancer Drug
Initiative: Majority Acquisition, Patent Strategy and Clinical
Development Along With New Partnership Proposal Involving Medicinal
Marijuana Drug Development
TORONTO, ON--(Marketwired - Mar 25, 2014) - Easton
Pharmaceuticals, Inc. (OTC: EAPH), a specialty pharmaceutical
company that owns, designs, develops, and markets an array of
topically-delivered drugs and therapeutic / cosmetic healthcare
products, announces it has entered into an agreement towards
securing majority control of the cancer drug Xilive, pending
certain conditions and a new partnership proposal towards medicinal
marijuana.
Easton is moving forward on its cancer drug Xilive based on the
encouraging survival and disease-free data from two late-stage,
long-term cancer survivors who have been on Xilive for several
years each. Easton has closed on a majority ownership agreement
with the inventor and current majority owners of the drug, but is
conditional upon receiving clarification that the drug is
patentable. Once the company receives confirmation, Easton will
then close on its agreement to dramatically increase and gain a
majority ownership position in Xilive with terms involving the
issuance of common shares in the company, following which the
company will proceed to focus on Xilive's development, formalize
and strengthen the patent estate and announce specifics on its
clinical development plan. Easton is able to disclose it has had
preliminary talks with several well respected clinical
investigators and CRO companies including with current advisors and
consultants to the company with experience in cancer drug
development, and intends to pursue their participation in Xilive's
clinical development once the patent and ownership issue has been
addressed.
Initial feedback on patients treated prior to Easton purchasing
its minority interest in Xilive has been extremely encouraging
although they were not performed under the supervision of
oncologists in a controlled study. Easton will formalize a clinical
plan aimed at "fast-track" approval in most controlled
jurisdictions. Since cancer is a disease which can cause death very
quickly, Easton, in consultation with its advisors and consultants
believes the clinical path towards a formal POC (Proof of Concept)
study could be very brief, and based on formal data from a well-run
POC study, could lead to initiation of approval stage (Phase
II/III) clinical studies in 2015 which is dependent on obtaining
adequate financing to complete. At this point if the data shows
similar results to the first few patients who have taken Xilive,
Easton believes it could license the drug to a major Pharmaceutical
company in the cancer drug arena. The drug can be currently
utilized only under the compassionate use exemption within the
United States, which calls for a patient or anyone wishing to be
administered the drug as a treatment for cancer to file necessary
paperwork with the food and drug administration to get approval for
its use.
In other developments, Easton Pharmaceuticals has submitted a
proposal to Vodis Innovative Pharmaceuticals and with one other
company who are both considered expert growers and companies
possessing the expertise and high technology extraction equipment
for a partnership agreement to extract certain ingredients from
different strains of marijuana plants allowing Easton to enter into
its own research and development towards utilizing its transdermal
delivery technology to produce a drug to treat various ailments and
conditions in which marijuana is now known to be effective at
treating. In addition, the company believes that an alternative
will one day exist where smoking and inhaling marijuana will be
replaced by a transdermal patch that can safely and effectively
deliver the medicinal and non-medicinal ingredients within cannabis
which would assist the many individuals who have lung and
respiratory problems and conditions. Although under current laws
this is not presently allowed in North America, it is allowed in
various other countries around the world. However, many believe
that the United States will be the first in North America in the
not too distant future to eventually allow for the complete
legalization of marijuana on a federal level just as the state of
Colorado has recently enacted. Any such agreements with Vodis or
any other companies would be separate from all other businesses
that would involve growing or distributing medicinal marijuana.
More detailed updates on this initiative will be released as they
develop.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company
involved in various industries including medical marijuana and who
owns, designs, develops, and markets topically-delivered drugs and
therapeutic / cosmetic healthcare products, focused on cancer and
other health issues related towards male and female sexual
dysfunction, wound healing, pain, motion sickness, scar and stretch
marks, cellulite, varicose veins and other conditions. The
company's gel formulation is thought to be an innovative and unique
transdermal delivery system. Easton Pharmaceuticals product
"VIORRA," is an over-the-counter aid for the treatment to
restore and improve vaginal moisture and elasticity which is
believed to have a positive effect on women's sexual desire and
arousal, FSAD (Female Sexual Arousal Disorder) the world market for
these female conditions are conservatively estimated to be in the
billions. VIORRA is a topical, daily-use product
classified by the FDA as containing Generally Recognized as Safe
ingredients.
For More Information Visit:
http://www.eastonpharmaceuticalsinc.com &
http://www.ashleybiomedical.com
Safe Harbor
This news release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
(The "Act"). In particular, when used in the preceding of
discussion, the words "anticipate," "pleased," "plan," "confident
that," "believe," "expect," "possible" or "intent to" and similar
conditional expressions are intended to identify forward-looking
statements within the meaning of the Act and are subject to the
safe harbor created by the Act. Such statements are subject to
certain risks and uncertainties and actual results could differ
materially from those expressed in any of the forward-looking
statements. Such risks and uncertainties include, but are not
limited to, market conditions, general acceptance of the company's
products and technologies, competitive factors, the ability to
successfully complete additional or adequate financing, government
approvals or changes to proposed laws and other risks and
uncertainties further stated in the company's financial reports and
filings.
Contact: Carla Pepe Easton Pharmaceuticals Inc. Tel: +1(416)
619-0291 Tel: +1(347) 284-0192 email:
info@eastonpharmaceuticalsinc.com email:
info@ashleybiomedical.com
Easton Pharmaceuticals (CE) (USOTC:EAPH)
Historical Stock Chart
From Jul 2024 to Aug 2024
Easton Pharmaceuticals (CE) (USOTC:EAPH)
Historical Stock Chart
From Aug 2023 to Aug 2024